Build metabolic health as the foundation all other longevity practices rest on

Insulin resistance underlies the majority of the four horsemen — addressing metabolic health first creates the largest downstream health returns.

Why it works

Insulin resistance — the state in which cells become less responsive to insulin signals — creates a cascade: hyperinsulinemia, atherogenic dyslipidemia (high triglycerides, low HDL, small dense LDL), visceral fat accumulation, chronic inflammation, and elevated cancer risk through IGF-1 signaling. Attia’s framework places metabolic health as the platform because it is both highly modifiable through behavior and because its impairment accelerates most of the four horsemen simultaneously.

How to do it

1. Test your fasting insulin (not just fasting glucose) — insulin rises years before glucose becomes abnormal, making it a more sensitive early marker.
2. Reduce postprandial glucose spikes with meal composition (protein and fat before carbohydrate), portion control, and post-meal walking.
3. Build lean muscle mass — skeletal muscle is the largest glucose disposal organ, and its mass determines how much glucose can be cleared without insulin.
4. If overweight, even modest fat loss (5–10 % of body weight) produces disproportionate improvements in insulin sensitivity.

Evidence

Insulin resistance is a well-validated risk factor for cardiovascular disease, type 2 diabetes, and cancer. Fasting insulin is a validated predictor of metabolic syndrome before glucose becomes abnormal. Resistance training and fat loss are well-established interventions for insulin sensitivity. (observational)

Fasting insulin testing is not universally standardized; assay variation between labs is significant. Normal ranges vary and are debated — compare results within the same lab over time.

Sources

• DeFronzo & Tripathy (2009), "Skeletal muscle insulin resistance is the primary defect in type 2 diabetes," Diabetes Care

Common mistake

Focusing on fasting glucose alone and missing the 10–20 year window when insulin is already elevated but glucose is still normal — the highest-leverage intervention window.